BAX logo

BAX Baxter International Inc.

New York Stock Exchange · Medical - Instruments & Supplies · Healthcare

$26.73
-0.32 (-1.18%)

Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devic…

Market Cap: $13.82Bwww.baxter.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

135
135
Aug 17Aug 17

Quote

Day Range
$26.59 – $27.13
52-Week Range
$15.73 – $30.00
Volume
$3.99M
Market Cap
$13.82B
50-Day Avg
$22.94
200-Day Avg
$19.80
Prev Close
$27.05
Open
$27.01

Valuation & Ratios

P/E Ratio
-10.92
EPS
$-1.87
P/B Ratio
1.60
P/S Ratio
0.87
Debt/Equity
1.63
Current Ratio
2.31
Dividend Yield
+3.5%
Gross Margin
+30.1%

Returns & Efficiency

Return on Equity
-15.6%
Return on Assets
-4.8%
FCF Yield
+3.3%
EV/EBITDA
23.29

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$11.24B$-957.00M$-1.75
2024$10.64B$-649.00M$-1.27
2023$10.36B$2.66B$5.25
2022$10.06B$-2.43B$-4.83
2021$12.15B$1.28B$2.56

Social Signal Score

85
5d
85
1 mentions
30d
85
1 mentions
60d
85
1 mentions
90d
85
1 mentions
marketaux: 1

Earnings

Thu, Oct 29(in 2 months)

Consensus estimate $0.52 per share

5of 7 quarters beat consensus

Typical surprise +13.8% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, Jul 30$0.56 vs $0.37beat
  • Thu, Apr 30$0.36 vs $0.31beat
  • Thu, Feb 12$0.44 vs $0.53miss
  • Thu, Oct 30$0.69 vs $0.60beat
  • Thu, Jul 31$0.59 vs $0.60miss
  • Thu, May 1$0.55 vs $0.48beat

Estimates and results for BAX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Insider trading

Open-market buys and sells by BAX officers and directors.

No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.

100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.

Valuation

BAXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • News (Marketaux)acquirersmultiple.com·2h ago·Positive

    Rich Pzena’s Latest Portfolio: Top 10 Holdings & Biggest Moves Portfolio Snapshot Total Portfolio Valu[+358 characters]

    View source ↗